Autolus Therapeutics to Participate in Upcoming Investor Conference

Rhea-AI Summary

Autolus Therapeutics (Nasdaq: AUTL) will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. CEO Dr. Christian Itin will join a fireside chat on June 30, 2026 at 9:00am EDT / 14:00 BST.

The live webcast and a 90-day replay will be accessible via the company’s Investor Relations & Media Events webpage.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON and GAITHERSBURG, Md., June 25, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announced that the Company will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference.

Autolus Chief Executive Officer Dr. Christian Itin will present in a Fireside Chat on Tuesday, June 30, 2026 at 9:00am EDT / 14:00pm BST.

A webcast of the fireside chat will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at https://www.autolus.com/investor-relations-media/events/. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL^®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.

Contact:

Amanda Cray
+1 617-967-0207
a.cray@autolus.com

FAQ

When will Autolus Therapeutics (NASDAQ: AUTL) present at the H.C. Wainwright Cell Therapy Virtual Conference?

Autolus Therapeutics will present a fireside chat on June 30, 2026 at 9:00am EDT / 14:00 BST. According to Autolus, CEO Dr. Christian Itin will represent the company at this virtual investor event.

Who is representing Autolus Therapeutics (AUTL) at the June 30, 2026 H.C. Wainwright conference?

Autolus Therapeutics will be represented by Chief Executive Officer Dr. Christian Itin. According to Autolus, he will participate in a fireside chat during the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference.

How can investors access the Autolus Therapeutics (AUTL) June 30, 2026 conference webcast?

Investors can access the live webcast on the Events page in the Investor Relations & Media section of Autolus’ website. According to Autolus, the webcast link will be posted there for virtual attendees.

Will there be a replay of the Autolus Therapeutics (NASDAQ: AUTL) H.C. Wainwright fireside chat?

Yes, a replay of the Autolus fireside chat will be available for 90 days. According to Autolus, the archived webcast will be hosted on the company’s website after the June 30, 2026 presentation.

What type of event is Autolus Therapeutics (AUTL) joining at the H.C. Wainwright conference on June 30, 2026?

Autolus Therapeutics is joining a fireside chat at the virtual conference. According to Autolus, this session with CEO Dr. Christian Itin is part of the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference.